The Zealand Pharma stock drop sent shockwaves through the market on Monday, as shares of the weight loss drug maker plummeted by as much as 26% after fresh data on its experimental medicine raised serious concerns about side effects.

Key Points

• Shares of Zealand Pharma tumbled as much as 26% following new data on an experimental obesity treatment that spotlighted troubling side effects.
• Barclays analysts summed up the issue bluntly: “Safety/tolerability remains the key issue.”
• The decline adds to an already painful year, with Zealand shares down nearly 50% year-to-date.

What Triggered the Sell-Off

The Danish drugmaker reported that its drug survodutide — which it has licensed to privately held Boehringer Ingelheim — met its key targets in a late-stage study. However, the encouraging efficacy results were overshadowed by a striking safety figure: 19% of patients dropped out of the study due to gastrointestinal events, compared to just 2.9% of those on placebo.

Analysts were quick to flag the problem. Barclays noted, “Overall, we view the safety/tolerability as disappointing for [Zealand], despite data confirming some interesting body-composition/liver signals.”

The firm warned that the high discontinuation rate — with more than 40% of patients reporting vomiting — could limit the drug’s commercial potential as a treatment for obesity or fatty liver disease.

By the latest reading, Zealand Pharma shares were down 25%, sitting firmly at the bottom of the pan-European Stoxx 600 index and deepening a nearly 50% slide for the year.

Breaking Down the Trial Results

Survodutide was tested in adults living with obesity or overweight without type 2 diabetes over a 76-week period. The efficacy numbers themselves were impressive — topline data from April showed average weight loss of up to 16.6%, versus 3.2% with placebo.

But for analysts, tolerability was the dealbreaker. Citi struck a similarly cautious tone, writing: “A 19% treatment discontinuation rate due to… adverse events… is not a rounding error, and nausea, vomiting, diarrhea, and constipation incidence at the levels reported here sit well above what we consider commercially viable against [rival drugs] tirzepatide and semaglutide.”

A Rough Stretch for Zealand

This setback comes roughly three months after Zealand stock suffered its worst day on record. That earlier plunge followed a disappointing trial of another of its experimental anti-obesity drugs, petrelintide, which delivered lower-than-expected weight loss results.

Additional petrelintide data released last Friday offered, in Barclays’ words, “incremental detail around [its] clinical profile, but little to change our view since the topline in March.” The analysts noted that petrelintide — which Zealand is developing alongside Roche — looks appealing on tolerability, but its efficacy doesn’t appear as strong as Eli Lilly’s amylin candidate, eloralintide, or other incretin-based obesity treatments already on the market.

An Increasingly Crowded Market

The broader weight loss drug market is currently dominated by two giants:

• Novo Nordisk, which sells semaglutide under the brand names Wegovy and Ozempic
• Eli Lilly, which markets tirzepatide as Zepbound and Mounjaro

Yet a wave of hopeful challengers is now testing their own anti-obesity treatments. Beyond Zealand Pharma — which is partnering with both Roche and Boehringer Ingelheim — heavyweights like Amgen and AstraZeneca are also vying for a piece of the lucrative market.

This intensifying competition has ramped up the pressure on companies to differentiate their products. Several areas are emerging as key battlegrounds, including muscle mass preservation, oral drug options, obesity-related diseases, and broader weight management.

Investec analyst Jimmy Muchechetere told CNBC’s “Squawk Box Europe” on Monday that while Novo’s Wegovy and Lilly’s pill offerings have dominated so far, even more players are poised to enter the market soon.

Zealand’s Counterargument

For its part, Zealand Pharma has long pushed back against what it calls the “weight loss olympics,” arguing that the industry places an outsized emphasis on the percentage of weight lost.

CEO Adam Steensberg told CNBC in March that he was “extremely certain” the industry would shift “towards tolerability” — meaning how well patients can actually handle a medication’s side effects.

“I think very, very soon, people start to realize that it’s not about that weight loss number, it’s about how you achieve that weight loss number,” Steensberg said.

The Takeaway

Monday’s plunge underscores a growing reality in the booming weight loss drug space: efficacy alone is no longer enough. As competition heats up and patients have more options than ever, tolerability and side-effect profiles are becoming just as critical to a drug’s commercial success. For Zealand Pharma, the challenge now is convincing investors that its pipeline can compete not just on weight loss results, but on how comfortably patients can stick with treatment — a test its latest data has made considerably harder. None of this constitutes investment advice, and anyone weighing a position should consider their own circumstances and consult a professional.